At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 795 enrolled
Drug / intervention
afatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy
In Brief
A Phase 3 clinical trial evaluating afatinib and erlotinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 795 participants across 192 sites in 23 countries.
Detailed Summary
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesArgentina, Austria, Canada, Chile, China, Denmark, France, Germany, Greece, Hungary, India, Ireland, Italy, Mexico, Netherlands, Portugal, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartMar 2012
Primary CompletionOct 2013
Study CompletionDec 2017
TodayJul 2026
First PostedFeb 1, 2012
Enrollment StartMar 5, 2012
Primary CompletionOct 21, 2013
Study CompletionDec 27, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.4 years ago
Interventions
afatinibdrug
Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
erlotinibdrug
erlotinib taken once daily